siRNA

Based on the unique RNA nucleic acid synthesis technology (explained later), Bonac has developed a single-strand straight-chain RNA oligomer called Bonac Nucleic Acid (nkRNA and PnkRNA) which consists of about 60 bases4.

From the 5’ terminal to 3’ terminal, sense chain, 1st linker section (non-complementary section), antisense chain, and 2nd linker section (non-complementary section) are included, and all of these consist of RNA molecules.

nkRNA®

nkRNA®

From the 5’ terminal to 3’ terminal, sense chain, 1st linker section (non-complementary section), antisense chain, and 2nd linker section (non-complementary section) are included, and all of these consist of RNA molecules.

PnkRNA®

PnkRNA®

In the structure of nkRNA on the left side, the linker sections on both sides are replaced with amino acid proline “P” derivative.

Advantage of nkRNA® and PnkRNA®

1.Resistant to degradation

Susceptibility to degradation is a disadvantage of nucleic acid medicines, and research is being conducted globally to overcome this problem.
nkRNA® and PnkRNA® developed by Bonac have higher resistance to nuclease compared to siRNA.

< In vitro stabilities of BONAC Nucleic Acid (S7 uclease resistance test) >

2.Avoidance of response to innate immunity as adverse drug reaction

Since siRNA is perceived as foreign matter in the body, activation of innate immune response in the body as an adverse drug reaction has been considered a problem. In fact, this is said to be the main cause of a Phase Ⅲ study of siRNA under development being interrupted in the US.

However, Bonac Nucleic Acid avoids innate immune response due to its unique structure, suggesting that Bonac Nucleic Acid can be used as nucleic acid medicine with low incidence of adverse drug reactions.

ページ上部へ